Innate Pharma (IPHA) Change in Working Capital (2019 - 2025)

Innate Pharma has reported Change in Working Capital for 5 years, with the latest figure at -$2328.1 in Q4 2025.

• For the quarter ending Q4 2025, Change in Working Capital changed N/A year-over-year to -$2328.1; the trailing twelve-month figure through Dec 2025 stood at -$3.2 million (changed N/A YoY), and the FY2025 full-year result was -$2328.1, down 109.08% from the prior year.
• Change in Working Capital for Q4 2025 stood at -$2328.1, up from -$55486.9 in the prior quarter.
• The five-year high for Change in Working Capital was -$2328.1 in Q4 2025, with the low at -$1.8 million in Q2 2021.
• Historically, Change in Working Capital has averaged -$797731.3 across 3 years, with a median of -$705546.3 in 2022.
• Annual changes were most pronounced in 2021 — Change in Working Capital plunged 347.63% — and 2022, when it soared 96.88%.
• Innate Pharma's Change in Working Capital stood at -$1.4 million in 2021, then soared by 95.91% to -$55486.9 in 2022, then soared by 95.8% to -$2328.1 in 2025.
• The last three Change in Working Capital figures came in at -$2328.1 (Q4 2025), -$55486.9 (Q2 2022), and -$1.4 million (Q4 2021), per Business Quant data.